Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB SFCE 2009
2024-514844-10-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vincristine, carboplatin, cyclophosphamide, etoposide and thiotepa in retinoblastoma (Rb), sponsored by Institut Curie. Primary endpoint: Rate of extraocular relapses. Planned start Aug 2024; status: authorised.
02
Drugs
vincristinecarboplatincyclophosphamideetoposidethiotepa
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2024-514844-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514844-10-00.